其他真菌病当前治疗格局:隐球菌病、镰刀菌病与毛霉病
本文综述了隐球菌病、镰刀菌病和毛霉病三种全球流行但未纳入免疫抑制宿主抗真菌预防指南的侵袭性真菌病的抗真菌管理策略。随着生物标志物用于诊断筛查,抢先治疗概念在这些疾病中兴起;隐球菌病采用抢先或治疗策略而不涉及预防或经验性治疗,镰刀菌病可基于血清半乳甘露聚糖抗原监测采用抢先或诊断驱动方法,毛霉病因循环毛霉目DNA检测的可及性而在血液科出现抢先治疗概念。这些例子展示了在资源有限地区及难以诊断和治疗的侵袭性真菌病中实施抗真菌管理规划的挑战。
要点
- 隐球菌病管理采用抢先或治疗策略,不涉及预防或经验性抗真菌治疗。
- 侵袭性镰刀菌病可基于高危人群血清半乳甘露聚糖抗原监测采用抢先或诊断驱动方法。
- 毛霉病可在血液科因循环毛霉目DNA检测可及而采用抢先治疗概念。
核心结论
- 隐球菌病、镰刀菌病和毛霉病未纳入免疫抑制宿主抗真菌预防指南,其抗真菌管理策略与曲霉病和念珠菌病不同。
- 抢先抗真菌治疗概念已在这些侵袭性真菌病中随生物标志物诊断筛查策略的实施而出现。
研究设计与样本
- 综述,比较隐球菌病、镰刀菌病和毛霉病与主要侵袭性真菌病在抗真菌管理策略上的机会与考量。
主要发现
- 隐球菌病是全球最常见的侵袭性真菌病,管理一般采用抢先或治疗策略,不涉及预防或经验性抗真菌治疗。
- 侵袭性镰刀菌病是血液恶性肿瘤患者中第二常见的非曲霉霉菌感染,可基于高危人群血清半乳甘露聚糖抗原监测采用抢先或诊断驱动方法管理。
- 毛霉病可在接受对毛霉目无活性抗真菌药的血液科或实体器官移植受者中作为突破性侵袭性真菌病出现。
- 毛霉病抢先治疗概念的出现源于近期循环毛霉目DNA检测的可及。
临床怎么用
- 隐球菌病可采用抢先或治疗策略,抗真菌管理结局可能因当地资源可及性而异。
- 镰刀菌病可在高危人群监测血清半乳甘露聚糖抗原,采用抢先或诊断驱动方法。
- 毛霉病可在血液科利用循环毛霉目DNA检测实施抢先治疗。
- 抗真菌管理规划降低侵袭性镰刀菌病负担的成功取决于快速诊断策略的制定和实施,以实现早期适当治疗。
局限性
- 在资源有限地区以及难以诊断和治疗的侵袭性真菌病中实施抗真菌管理规划存在挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Compared with major invasive mycoses such as aspergillosis and candidiasis, the antifungal stewardship management strategies of other fungal diseases have different opportunities and considerations. Cryptococcosis, fusariosis and mucormycosis are globally prevalent invasive fungal diseases (IFDs), but are not currently included in antifungal prophylaxis guidelines for immunocompromised hosts. Since the implementation of biomarkers as part of diagnostic screening strategies, the concept of pre-emptive antifungal therapy has emerged for these IFDs. Management of cryptococcosis, the most common IFD worldwide, generally utilizes a pre-emptive or therapeutic strategy that does not involve prophylaxis or empirical antifungal treatment strategies. Antifungal stewardship outcomes for cryptococcosis may vary according to the availability of local resources. Invasive fusariosis, the second-most common form of non-Aspergillus mould infection among haematological malignancy patients, can be managed with pre-emptive (or diagnostic-driven) approaches based on the monitoring of serum galactomannan (GM) antigen in increased-risk populations. The success of antimicrobial stewardship programmes in decreasing the burden of invasive fusariosis in selected patient populations depends on the development and implementation of rapid diagnostic strategies for early and appropriate administration of therapy. Mucormycosis may emerge as a breakthrough IFD in haematology or solid organ transplant recipients receiving antifungals that lack activity against Mucorales. The concept of pre-emptive antifungal therapy has thus arisen for mucormycosis in the haematology setting because of the recent availability of circulating Mucorales DNA measurement. These examples demonstrate the challenges of implementing antifungal stewardship programmes in areas with limited resources, as well as in IFDs that are difficult to diagnose and treat.
引用
- Lortholary O, Fernández-Ruiz M, Perfect JR, et al. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). J Antimicrob Chemother. 2016. PMID: 27880667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。